| Cancer stem cells (CSCs) with their self-renewal ability are accepted as cells which initiate
tumors. CSCs are regarded as interesting targets for novel anticancer therapeutic agents because of their
association with tumor recurrence and resistance to conventional therapies, including radiotherapy and
chemotherapy. Chimeric antigen receptor (CAR)-T cells are engineered T cells which express an artificial
receptor specific for tumor associated antigens (TAAs) by which they accurately target and kill cancer
cells. In recent years, CAR-T cell therapy has shown more efficiency in cancer treatment, particularly
regarding blood cancers. The expression of specific markers such as TAAs on CSCs in varied cancer types
makes them as potent tools for CAR-T cell therapy. Here we review the CSC markers that have been previously
targeted with CAR-T cells, as well as the CSC markers that may be used as possible targets for |